Christopher Raymond
Stock Analyst at Piper Sandler
(4.37)
# 418
Out of 4,412 analysts
77
Total ratings
63.95%
Success rate
11.6%
Average return
Main Sectors:
26 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSHA Taysha Gene Therapies | Initiates: Overweight | $9 | $2.39 | +276.57% | 1 | Apr 9, 2024 | |
| QTTB Q32 Bio | Initiates: Overweight | $45 | $28.02 | +60.60% | 1 | Apr 2, 2024 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $11 → $21 | $16.86 | +24.56% | 5 | Mar 8, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $115 → $107 | $80.91 | +32.25% | 6 | Feb 23, 2024 | |
| ARDX Ardelyx | Maintains: Overweight | $12 → $15 | $6.42 | +133.64% | 4 | Feb 23, 2024 | |
| BIIB Biogen | Maintains: Overweight | $350 → $325 | $208.90 | +55.58% | 8 | Feb 14, 2024 | |
| ALVR AlloVir | Downgrades: Neutral | $27 → $1.5 | $0.80 | +88.18% | 2 | Dec 22, 2023 | |
| BHVN Biohaven Pharmaceutical Holding Company | Maintains: Overweight | $29 → $36 | $38.97 | -7.62% | 5 | Nov 15, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $7 → $5 | $1.06 | +371.70% | 3 | Nov 3, 2023 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $885 → $895 | $883.20 | +1.34% | 3 | Nov 3, 2023 | |
| DCPH Deciphera Pharmaceuticals | Upgrades: Overweight | $18 → $23 | $14.65 | +57.00% | 1 | Oct 30, 2023 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $135 → $130 | $44.24 | +193.85% | 4 | Oct 25, 2023 | |
| IOBT IO Biotech | Initiates: Overweight | $10 | $1.42 | +604.23% | 1 | Sep 28, 2023 | |
| ABBV AbbVie | Maintains: Overweight | $163 → $170 | $159.62 | +6.50% | 7 | Jul 28, 2023 | |
| COGT Cogent Biosciences | Maintains: Overweight | $22 | $6.02 | +265.45% | 1 | Jun 12, 2023 | |
| AKBA Akebia Therapeutics | Upgrades: Overweight | $2 → $4 | $1.34 | +198.51% | 3 | May 31, 2023 | |
| MGTX MeiraGTx Holdings | Maintains: Overweight | $26 → $25 | $4.80 | +420.83% | 1 | May 12, 2023 | |
| VRTX Vertex Pharmaceuticals | Assumes: Overweight | $385 | $397.48 | -3.14% | 4 | May 4, 2023 | |
| AMGN Amgen | Maintains: Overweight | $293 → $288 | $269.98 | +6.67% | 9 | Apr 28, 2023 | |
| AGIO Agios Pharmaceuticals | Initiates: Overweight | $41 | $31.49 | +30.20% | 1 | Feb 3, 2023 | |
| ONON On Holding AG | Initiates: Overweight | $28 | $32.79 | -14.61% | 1 | Jul 26, 2022 | |
| BPMC Blueprint Medicines | Maintains: Neutral | $84 → $65 | $93.00 | -30.11% | 1 | May 19, 2022 | |
| NUVL Nuvalent | Initiates: Overweight | n/a | $66.86 | - | 1 | Aug 23, 2021 | |
| SLDB Solid Biosciences | Initiates: Neutral | n/a | $8.98 | - | 1 | Jul 12, 2021 | |
| ACRS Aclaris Therapeutics | Initiates: Overweight | n/a | $1.20 | - | 1 | Jun 15, 2021 | |
| INO Inovio Pharmaceuticals | Downgrades: Neutral | $96 | $10.57 | +808.23% | 2 | Mar 13, 2020 |
Taysha Gene Therapies
Apr 9, 2024
Initiates: Overweight
Price Target: $9
Current: $2.39
Upside: +276.57%
Q32 Bio
Apr 2, 2024
Initiates: Overweight
Price Target: $45
Current: $28.02
Upside: +60.60%
ALX Oncology Holdings
Mar 8, 2024
Maintains: Overweight
Price Target: $11 → $21
Current: $16.86
Upside: +24.56%
BioMarin Pharmaceutical
Feb 23, 2024
Maintains: Overweight
Price Target: $115 → $107
Current: $80.91
Upside: +32.25%
Ardelyx
Feb 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $6.42
Upside: +133.64%
Biogen
Feb 14, 2024
Maintains: Overweight
Price Target: $350 → $325
Current: $208.90
Upside: +55.58%
AlloVir
Dec 22, 2023
Downgrades: Neutral
Price Target: $27 → $1.5
Current: $0.80
Upside: +88.18%
Biohaven Pharmaceutical Holding Company
Nov 15, 2023
Maintains: Overweight
Price Target: $29 → $36
Current: $38.97
Upside: -7.62%
Karyopharm Therapeutics
Nov 3, 2023
Maintains: Overweight
Price Target: $7 → $5
Current: $1.06
Upside: +371.70%
Regeneron Pharmaceuticals
Nov 3, 2023
Maintains: Overweight
Price Target: $885 → $895
Current: $883.20
Upside: +1.34%
Deciphera Pharmaceuticals
Oct 30, 2023
Upgrades: Overweight
Price Target: $18 → $23
Current: $14.65
Upside: +57.00%
Ultragenyx Pharmaceutical
Oct 25, 2023
Maintains: Overweight
Price Target: $135 → $130
Current: $44.24
Upside: +193.85%
IO Biotech
Sep 28, 2023
Initiates: Overweight
Price Target: $10
Current: $1.42
Upside: +604.23%
AbbVie
Jul 28, 2023
Maintains: Overweight
Price Target: $163 → $170
Current: $159.62
Upside: +6.50%
Cogent Biosciences
Jun 12, 2023
Maintains: Overweight
Price Target: $22
Current: $6.02
Upside: +265.45%
Akebia Therapeutics
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $1.34
Upside: +198.51%
MeiraGTx Holdings
May 12, 2023
Maintains: Overweight
Price Target: $26 → $25
Current: $4.80
Upside: +420.83%
Vertex Pharmaceuticals
May 4, 2023
Assumes: Overweight
Price Target: $385
Current: $397.48
Upside: -3.14%
Amgen
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $269.98
Upside: +6.67%
Agios Pharmaceuticals
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $31.49
Upside: +30.20%
On Holding AG
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $32.79
Upside: -14.61%
Blueprint Medicines
May 19, 2022
Maintains: Neutral
Price Target: $84 → $65
Current: $93.00
Upside: -30.11%
Nuvalent
Aug 23, 2021
Initiates: Overweight
Price Target: n/a
Current: $66.86
Upside: -
Solid Biosciences
Jul 12, 2021
Initiates: Neutral
Price Target: n/a
Current: $8.98
Upside: -
Aclaris Therapeutics
Jun 15, 2021
Initiates: Overweight
Price Target: n/a
Current: $1.20
Upside: -
Inovio Pharmaceuticals
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $10.57
Upside: +808.23%